These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
683 related articles for article (PubMed ID: 30769947)
21. Potency and durability of T and B cell immune responses after homologous and heterologous vector delivery of a trimer-stabilized, membrane-displayed HIV-1 clade ConC Env protein. Perdiguero B; Hauser A; Gómez CE; Peterhoff D; Sideris E; Sorzano CÓS; Wilmschen S; Schaber M; Stengel L; Asbach B; Ding S; Von Laer D; Levy Y; Pantaleo G; Kimpel J; Esteban M; Wagner R Front Immunol; 2023; 14():1270908. PubMed ID: 38045703 [TBL] [Abstract][Full Text] [Related]
22. Envelope proteins of two HIV-1 clades induced different epitope-specific antibody response. Shrivastava T; Samal S; Tyagi AK; Goswami S; Kumar N; Ozorowski G; Ward AB; Chakrabarti BK Vaccine; 2018 Mar; 36(12):1627-1636. PubMed ID: 29429810 [TBL] [Abstract][Full Text] [Related]
27. Development and Evaluation of an Ebola Virus Glycoprotein Mucin-Like Domain Replacement System as a New Dendritic Cell-Targeting Vaccine Approach against HIV-1. Ao Z; Wang L; Azizi H; Olukitibi TA; Kobinger G; Yao X J Virol; 2021 Jul; 95(15):e0236820. PubMed ID: 34011553 [TBL] [Abstract][Full Text] [Related]
28. VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA. Jia M; Liberatore RA; Guo Y; Chan KW; Pan R; Lu H; Waltari E; Mittler E; Chandran K; Finzi A; Kaufmann DE; Seaman MS; Ho DD; Shapiro L; Sheng Z; Kong XP; Bieniasz PD; Wu X Cell Host Microbe; 2020 Jun; 27(6):963-975.e5. PubMed ID: 32315598 [TBL] [Abstract][Full Text] [Related]
29. Cleavage-Independent HIV-1 Trimers From CHO Cell Lines Elicit Robust Autologous Tier 2 Neutralizing Antibodies. Bale S; Martiné A; Wilson R; Behrens AJ; Le Fourn V; de Val N; Sharma SK; Tran K; Torres JL; Girod PA; Ward AB; Crispin M; Wyatt RT Front Immunol; 2018; 9():1116. PubMed ID: 29881382 [TBL] [Abstract][Full Text] [Related]
30. VSV-GP: a potent viral vaccine vector that boosts the immune response upon repeated applications. Tober R; Banki Z; Egerer L; Muik A; Behmüller S; Kreppel F; Greczmiel U; Oxenius A; von Laer D; Kimpel J J Virol; 2014 May; 88(9):4897-907. PubMed ID: 24554655 [TBL] [Abstract][Full Text] [Related]
31. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses. Zurawski G; Shen X; Zurawski S; Tomaras GD; Montefiori DC; Roederer M; Ferrari G; Lacabaratz C; Klucar P; Wang Z; Foulds KE; Kao SF; Yu X; Sato A; Yates NL; LaBranche C; Stanfield-Oakley S; Kibler K; Jacobs B; Salazar A; Self S; Fulp W; Gottardo R; Galmin L; Weiss D; Cristillo A; Pantaleo G; Levy Y J Virol; 2017 May; 91(9):. PubMed ID: 28202751 [TBL] [Abstract][Full Text] [Related]
32. Env-2dCD4 S60C complexes act as super immunogens and elicit potent, broadly neutralizing antibodies against clinically relevant human immunodeficiency virus type 1 (HIV-1). Killick MA; Grant ML; Cerutti NM; Capovilla A; Papathanasopoulos MA Vaccine; 2015 Nov; 33(46):6298-306. PubMed ID: 26432912 [TBL] [Abstract][Full Text] [Related]
33. Development of an HIV vaccine using a vesicular stomatitis virus vector expressing designer HIV-1 envelope glycoproteins to enhance humoral responses. Racine T; Kobinger GP; Arts EJ AIDS Res Ther; 2017 Sep; 14(1):55. PubMed ID: 28893277 [TBL] [Abstract][Full Text] [Related]
34. Improving the Expression and Purification of Soluble, Recombinant Native-Like HIV-1 Envelope Glycoprotein Trimers by Targeted Sequence Changes. Ringe RP; Ozorowski G; Yasmeen A; Cupo A; Cruz Portillo VM; Pugach P; Golabek M; Rantalainen K; Holden LG; Cottrell CA; Wilson IA; Sanders RW; Ward AB; Klasse PJ; Moore JP J Virol; 2017 Jun; 91(12):. PubMed ID: 28381572 [TBL] [Abstract][Full Text] [Related]
35. Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms. Murji AA; Qin JS; Hermanus T; Morris L; Georgiev IS Viruses; 2021 Jul; 13(7):. PubMed ID: 34372503 [TBL] [Abstract][Full Text] [Related]
36. Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. Quiñones-Kochs MI; Buonocore L; Rose JK J Virol; 2002 May; 76(9):4199-211. PubMed ID: 11932385 [TBL] [Abstract][Full Text] [Related]
37. Effect of HIV Envelope Vaccination on the Subsequent Antibody Response to HIV Infection. Ditse Z; Mkhize NN; Yin M; Keefer M; Montefiori DC; Tomaras GD; Churchyard G; Mayer KH; Karuna S; Morgan C; Bekker LG; Mlisana K; Gray G; Moodie Z; Gilbert P; Moore PL; Williamson C; Morris L mSphere; 2020 Jan; 5(1):. PubMed ID: 31996422 [TBL] [Abstract][Full Text] [Related]
38. Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D. McGuire AT; Glenn JA; Lippy A; Stamatatos L J Virol; 2014 Mar; 88(5):2645-57. PubMed ID: 24352455 [TBL] [Abstract][Full Text] [Related]
39. Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes. Das S; Boliar S; Mitra N; Samal S; Bansal M; Koff WC; Chakrabarti BK Retrovirology; 2016 Nov; 13(1):81. PubMed ID: 27871328 [TBL] [Abstract][Full Text] [Related]
40. Membrane bound Indian clade C HIV-1 envelope antigen induces antibodies to diverse and conserved epitopes upon DNA prime/protein boost in rabbits. Rangasamy SP; Menon V; Dhopeshwarkar P; Pal R; Vaniambadi KS; Mahalingam S Vaccine; 2016 May; 34(21):2444-2452. PubMed ID: 27032514 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]